Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
Renba LiangLiu YangXiaodong ZhuPublished in: Cancer control : journal of the Moffitt Cancer Center (2021)
Epidermal growth factor receptor (EGFR) is highly expressed in most of Nasopharyngeal carcinoma (NPC) samples and is associated with poor outcomes. Therefore, targeting EGFR may be a promising strategy to improve patient prognosis. Nimotuzumab is a humanized anti-EGFR monoclonal antibody. Recently, accumulating evidence has demonstrated that combination nimotuzumab and induction chemotherapy, radiotherapy, or concurrent chemoradiotherapy confer benefits for patients with NPC. Moreover, the side effects of such regimes are tolerable. In this review, we focus on the current data of nimotuzumab in clinical trials in the treatment of NPC.
Keyphrases
- epidermal growth factor receptor
- monoclonal antibody
- tyrosine kinase
- small cell lung cancer
- advanced non small cell lung cancer
- locally advanced
- clinical trial
- radiation therapy
- type diabetes
- early stage
- machine learning
- cancer therapy
- big data
- combination therapy
- metabolic syndrome
- drug delivery
- artificial intelligence
- radiation induced
- chemotherapy induced